
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS

Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Fecha de publicación: 16 mayo de 2019 Development of Functional Antibodies Directed to Human Dialyzable Leukocyte Extract Transferon®) Ver...
Sequencing Analysis and Identification of the Primary Peptide Component of the Dialyzable Leukocyte Extract “Transferon Oral”: The Starting Point...
Fecha de publicación: 6 de septiembre de 2022 In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2...
Efficacy, Pharmacokinetics, and Toxicity Profiles of Broad Anti-SARS-CoV-2 Neutralizing Antibody. VER MÁS
The dialyzable leukocyte extract TransferonTM inhibits tumor growth and brain metastasis in a murine model of prostate cancer. VER...
Taking advantage of a high-throughput flow cytometer for the implementation of an ADCC assay for regulatory compliance. VER MÁS
Phage Display Libraries for Antibody Therapeutic Discovery and Development. VER MÁS
Determination of Peptide Profile Consistency and Safety of Collagen Hydrolysates as Quality Attributes. VER MÁS

+52 (55) 5729 6000 Ext. 62543
Escuela Nacional de Ciencias Biológicas. Prolongación de Carpio y Plan de Ayala S/N, Del. Miguel Hidalgo, CDMX, C.P. 11340.
©2026 UDIBI